Anti-HIF-1A monoclonal antibody

Pre-made anti-HIF-1A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to HIF-1A/HIF1A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0067-Ab-1/ GM-Tg-hg-IP0067-Ab-2Anti-Human HIF-1A/HIF1A monoclonal antibodyHuman
GM-Tg-rg-IP0067-Ab-1/ GM-Tg-rg-IP0067-Ab-2Anti-Rat HIF-1A/HIF1A monoclonal antibodyRat
GM-Tg-mg-IP0067-Ab-1/ GM-Tg-mg-IP0067-Ab-2Anti-Mouse HIF-1A/HIF1A monoclonal antibodyMouse
GM-Tg-cynog-IP0067-Ab-1/ GM-Tg-cynog-IP0067-Ab-2Anti-Cynomolgus/ Rhesus macaque HIF-1A/HIF1A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0067-Ab-1/ GM-Tg-felg-IP0067-Ab-2Anti-Feline HIF-1A/HIF1A monoclonal antibodyFeline
GM-Tg-cang-IP0067-Ab-1/ GM-Tg-cang-IP0067-Ab-2Anti-Canine HIF-1A/HIF1A monoclonal antibodyCanine
GM-Tg-bovg-IP0067-Ab-1/ GM-Tg-bovg-IP0067-Ab-2Anti-Bovine HIF-1A/HIF1A monoclonal antibodyBovine
GM-Tg-equg-IP0067-Ab-1/ GM-Tg-equg-IP0067-Ab-2Anti-Equine HIF-1A/HIF1A monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0067-Ab-1/ GM-Tg-hg-IP0067-Ab-2; GM-Tg-rg-IP0067-Ab-1/ GM-Tg-rg-IP0067-Ab-2;
GM-Tg-mg-IP0067-Ab-1/ GM-Tg-mg-IP0067-Ab-2; GM-Tg-cynog-IP0067-Ab-1/ GM-Tg-cynog-IP0067-Ab-2;
GM-Tg-felg-IP0067-Ab-1/ GM-Tg-felg-IP0067-Ab-2; GM-Tg-cang-IP0067-Ab-1/ GM-Tg-cang-IP0067-Ab-2;
GM-Tg-bovg-IP0067-Ab-1/ GM-Tg-bovg-IP0067-Ab-2; GM-Tg-equg-IP0067-Ab-1/ GM-Tg-equg-IP0067-Ab-2
Products NameAnti-HIF-1A/HIF1A monoclonal antibody
Formatmab
Target NameHIF-1A
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-HIF-1A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0067-Ag-1Recombinant multi-species HIF1A/ HIF-1A/ HIF-1-alpha protein
    ORF Viral VectorpGMLV000495human HIF1A Lentivirus plasmid
    ORF Viral VectorvGMLV000323human HIF1A Lentivirus particle
    ORF Viral VectorvGMLV000727human HIF1A Lentivirus particle
    ORF Viral VectorpGMAD000098human HIF1A Adenovirus plasmid
    ORF Viral VectorvGMLV000495human HIF1A Lentivirus particle
    ORF Viral VectorpGMLV000727human HIF1A Lentivirus plasmid
    ORF Viral VectorpGMLV000323human HIF1A Lentivirus plasmid
    ORF Viral VectorvGMAD000098human HIF1A Adenovirus particle
    ORF Viral VectorpGMAD000326rat Hif1a Adenovirus plasmid
    ORF Viral VectorpGMAAV000349Norway rat Hif1a AAV plasmid
    ORF Viral VectorpGMLPm004780mouse Hif1a Lentivirus plasmid
    ORF Viral VectorvGMAD000326rat Hif1a Adenovirus particle
    ORF Viral VectorvGMAAV000349Norway rat Hif1a AAV particle
    ORF Viral VectorvGMLPm004780mouse Hif1a Lentivirus particle


    Target information

    Target IDGM-IP0067
    Target NameHIF-1A
    Gene ID3091,15251,29560,704678,480348,101083686,281814,100061166
    Gene Symbol and SynonymsbHLHe78,HIF-1-alpha,HIF-1A,HIF-1alpha,HIF1,HIF1-ALPHA,HIF1A,HIF1alpha,MOP1,PASD8
    Uniprot AccessionQ16665,O35800,Q9XTA5
    Uniprot Entry NameHIF1A_HUMAN,HIF1A_RAT,HIF1A_BOVIN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseCancer
    Gene EnsemblENSG00000100644
    Target ClassificationTumor-associated antigen (TAA)

    The target: HIF-1A, gene name: HIF1A, also named as HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1, PASD8, bHLHe78. This gene encodes the alpha subunit of transcription factor hypoxia-inducible factor-1 (HIF-1), which is a heterodimer composed of an alpha and a beta subunit. HIF-1 functions as a master regulator of cellular and systemic homeostatic response to hypoxia by activating transcription of many genes, including those involved in energy metabolism, angiogenesis, apoptosis, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. HIF-1 thus plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Jul 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.